Aquestive Reports Positive Anaphylm Data, Targets Q3 NDA Resubmission
AQST sits 37% above its 52-week low of $2.93.
Summary
Aquestive reported positive human factors and PK study results for Anaphylm, addressing FDA concerns and supporting a planned NDA resubmission in Q3 2026. The data significantly de-risk the lead program.
Key Events · Product Development and Regulatory · AQST
-
Positive Anaphylm Study Results
A redesigned package slashed median pouch opening time from 17 seconds to just 3 seconds and cut incorrect film placement by over 80%, according to the human factors study. The PK study confirmed that self-administration matches clinician-administered delivery, and even deliberate top-of-tongue misplacement still triggered a clinically meaningful pharmacodynamic response.
-
Addresses FDA Complete Response Letter
The findings directly resolve every deficiency flagged in the January 2026 CRL — pouch opening difficulty, incorrect film placement, chewing, and premature removal. Notably, no participants in the new study chewed or removed the film.
-
NDA Resubmission on Track for Q3 2026
Management plans to include the new data in its Anaphylm NDA resubmission, expected in the third quarter of 2026 — less than eight months after receiving the CRL.
-
De-risks Lead Asset
As Aquestive's primary value driver, Anaphylm now faces materially lower regulatory risk. The positive results bolster the path to potential approval as the first non-invasive, orally delivered epinephrine product.
Analysis · AQST · Life Sciences
Aquestive announced positive topline results from human factors and pharmacokinetic studies for its lead product candidate, Anaphylm, directly addressing the deficiencies cited in the FDA's January 2026 Complete Response Letter. The revised packaging dramatically improved usability — median pouch opening time fell from 17 seconds to 3 seconds, and incorrect film placement dropped over 80%. Self-administration PK was comparable to clinician-administered, and even purposeful misplacement on top of the tongue produced a clinically meaningful pharmacodynamic response. These results clear a major regulatory hurdle and support the planned NDA resubmission in Q3 2026, keeping the company on track for a potential approval that would make Anaphylm the first non-invasive, orally delivered epinephrine product. The news materially de-risks the Anaphylm program and strengthens the investment thesis for a $494M market cap company whose future hinges on this single asset.
At the time of this filing, AQST was trading at $4.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $494.3M. The 52-week trading range was $2.93 to $7.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.